Trastuzumab Deruxtecan Prolongs OS in Second-Line Treatment for Patients with HER2-positive Metastatic Gastric or GEJ Adenocarcinoma By Ogkologos - July 2, 2025 119 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the DESTINY-Gastric04 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO’s Special Consultative Status with United Nations Economic and Social Council (UN ECOSOC) Confirmed Until 2028 EMA Recommends Extension of Indications for Selumetinib ESMO Calls for Urgent Changes to the in Vitro Diagnostic Medical Devices Regulation (IVDR) in Order to Safeguard Cancer Research in Europe MOST POPULAR FDA Approves Idecabtagene Vicleucel for Multiple Myeloma April 7, 2021 Cancer in My Community: Caring for Children With Cancer in Armenia July 2, 2020 How to Get More Support From Your Oncology Pharmacist During Cancer February 24, 2021 Mothers Raise Girls Together After Discovering They Were Swapped At Birth September 25, 2021 Load more HOT NEWS What My Mother’s Cancer Diagnosis Taught Me About Supporting a Loved... Courageous children receive Star Awards in virtual celebration No OS Benefit in EGFR T790M Advanced NSCLC Treated with Osimertinib... Woman with Breast Cancer May Have Saved Her Twin’s Life by...
